Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, May 2 2022

Full Issue

Moderna's Omicron-Tailored Booster To Be Largely Available This Fall

Moderna's chief medical officer said the drugmaker will have "large amounts" of its bivalent covid booster shot by then, and that its vaccine for the youngest kids would be ready for FDA review in June. Meanwhile, pressure grows on the agency to move quickly toward approval.

The Hill: Moderna Expects ‘Large Amounts’ Of Omicron Booster Available By Fall

Moderna’s Chief Medical Officer Paul Burton said on Sunday that his company was preparing to provide large amounts of its vaccine booster against omicron and other COVID-19 variants this fall. “We’re confident by the fall of this year we should have large amounts of that new booster vaccine that will protect against Omicron and other variants,” Burton said in an interview on CBS’s “Face the Nation.” Last month, Moderna announced that its new bivalent COVID-19 booster shot was more effective against all variants than the company’s currently available coronavirus vaccine. (Beals, 5/1)

Reuters: Moderna Says Its Vaccine For Ages Under 6 Will Be Ready For U.S. Review In June

Moderna Inc's chief medical officer said on Sunday the company's vaccine for children under 6 years old will be ready for review by a Food and Drug Administration panel when it meets in June. Moderna sought emergency use authorization from the FDA on Thursday. An advisory panel of experts to the U.S. drug regulator will meet in June to review the request. (Chiacu, 5/2)

Pressure rises for a June rollout —

Axios: Pressure Builds For COVID Vaccines Approval For Littlest Kids

Moderna's request for authorization of its COVID-19 vaccine in children under six years is amping up pressure on the Food and Drug Administration to act quickly on the shots. Thursday's request from the vaccine maker threw another wrinkle in the delicate regulatory dance over when kids under 5 can be vaccinated at a time when plenty of parents are expressing growing frustration with the wait. The FDA would prefer to evaluate data and simultaneously make decisions about how Moderna and Pfizer-BioNTech's vaccines work on small children, to give parents more of a comparison, the New York Times writes. That could take as long as June. (Reed, 5/2)

The Washington Post: Vaccines For Young Kids Could Be Available As Soon As June, A Top FDA Official Says

A top Food and Drug Administration official pledged Friday not to delay the rollout of coronavirus vaccines for the youngest children and said at least one of the two shots under review could become available in June. The remarks by Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, came in an interview about the agency’s new, but tentative, timeline for handling vaccine issues during the next two months. The FDA announced plans to convene meetings with its outside advisers on June 8, 21 and 22 to consider emergency use authorizations for pediatric coronavirus shots and to hold additional sessions for other pressing vaccine matters. (McGinley and Johnson, 4/29)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF